2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4522 Incidence and prognostic impact of venous thromboembolism in newly diagnosed peripheral T-cell lymphoma: A real-world cohort study

Vladimir Otasevic, MD, PhD, Darko Antic Sr, MD, PhD2, Lanzhu Yue, MD, PhD3, Maria Ahmad, MD4, Kausik Maiti, MD5, Nancy Lunney VI, MA6, Darko Dabic7, Chris Learn, PhD8, Heidi Cho, MD9
1 Parexel International, Raleigh, North Carolina, United States
2 Clinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
3 Parexel International, Raleigh, North Carolina, United States
4 Parexel International, Raleigh, North Carolina, United States
5 Parexel International, Raleigh, North Carolina, United States
6 Parexel International, Raleigh, North Carolina, United States
7 Parexel International, Raleigh, North Carolina, United States
8 Parexel International, Raleigh, North Carolina, United States
9 Parexel International, Raleigh, North Carolina, United States

Incidence and prognostic impact of venous thromboembolism in newly diagnosed peripheral T-cell lymphoma: a real-world cohort study

Vladimir Otasevic1, Darko Antic2,3, Lanzhu Yue1, Maria Ahmad1, Kausik Maiti1, Nancy Lunney1, Darko Dabic1, Chris Learn1, Heidi Cho1

1 Parexel International, Raleigh, NC, USA; 2 Clinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia; 3 Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Introduction: Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of rare and predominantly aggressive mature T-cell neoplasms with generally unfavorable outcomes. Venous thromboembolism (VTE) is a common complication in patients with cancer and has been associated with increased morbidity and mortality, particularly in aggressive lymphomas. Despite this, the burden and prognostic impact of VTE in PTCL remain poorly characterized due to the rarity of these malignancies and their limited representation in prior studies. The present study evaluated the frequency of VTE in newly diagnosed patients with PTCL and explored its impact on overall survival (OS) in a real-world data (RWD) setting.

Methods: A retrospective analysis of RWD was conducted using TriNetX Dataworks Global database on 23rd July 2026. Two cohorts were analyzed: 1) PTCL patients who developed VTE within 6 months of PTCL diagnosis and 2) PTCL patients who did not develop VTE within 6 months of PTCL diagnosis. Kaplan-Meier analysis, log-rank test, hazard ratios (HR), risk ratios (RR), and 95% confidence intervals (CI) were used to assess the primary outcomes, which were risk of death and OS. Propensity score matching (PSM) was performed using age, sex, race, body mass index, and presence of a central venous catheter (CVC) to reduce baseline imbalance between cohorts. Sensitivity analyses were conducted using alternative exposure definitions of VTE occurring within 3 months and within 12 months of PTCL diagnosis to assess the robustness of the findings.

Results: We identified 12,546 adult patients with PTCL for whom data on VTE development within 6 months of diagnosis were available. The patients’ median age (range) at the index event (PTCL diagnosis) for Cohort 1 (PTCL patients who developed VTE within 6 months) and Cohort 2 (PTCL patients without VTE within the first 6 months) was 70 (18-90). Among 12,546  patients with PTCL, 962 (7.7%) developed a first occurrence of VTE within 6 months of diagnosis. During the 3-year follow-up from the index event (PTCL diagnosis), PTCL patients who developed VTE had a statistically significantly higher risk of death than those without VTE (RR 1.863, 95% CI 1.740-1.995). PTCL patients with VTE had a statistically significantly inferior 3-year OS probability and a higher mortality risk during the 3-year follow-up period (41.7% vs. 65.7% survival probability at 3 years from the index event, log-rank test, χ2=249.994, p<0.001; HR 2.115, 95% CI 1.924-2.326). After PSM for covariates (age at index event, sex, race, body mass index, and presence of CVC), PTCL patients with VTE still had a statistically significantly higher risk of death than those without VTE during the 3-year follow-up from the index event (RR 1.849, 95% CI 1.641- 2.084). In addition, PTCL patients with VTE still had a statistically significantly inferior 3-year OS probability and a higher mortality risk over the 3-year follow-up period (41.6% vs. 66.3% survival probability at 3 years from the index event, log-rank test, χ2=101.28, p<0.001; HR 2.119, 95% CI 1.825-2.462). The association remained robust across sensitivity analyses using alternative VTE ascertainment windows (3 months and 12 months after PTCL diagnosis), with propensity score-matched HRs ranging from 1.757 to 2.052. Major limitations include the absence of performance status data, treatment response information, and patient-level clinical detail inherent to aggregated real-world data analyses.

Conclusions: PTCL patients who developed VTE within 6 months of diagnosis experienced substantially inferior overall survival, with an approximately two-fold higher hazard of death compared with PTCL patients without VTE. Further studies using patient-level data and more comprehensive adjustment for disease-related confounders are warranted to validate these findings.

Vladimir Otasevic, MD, PhD: No relevant conflicts of interest to declare.